Affordable Access

deepdyve-link
Publisher Website

Can we selectively target AML stem cells?

Authors
  • Jordan, Craig T1
  • 1 Division of Hematology, University of Colorado Anschutz Campus, Denver, CO, USA. Electronic address: [email protected] , (Jordan)
Type
Published Article
Journal
Best practice & research. Clinical haematology
Publication Date
Dec 01, 2019
Volume
32
Issue
4
Pages
101100–101100
Identifiers
DOI: 10.1016/j.beha.2019.101100
PMID: 31779978
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

De novo acute myeloid leukemia (AML) leukemia stem cell (LSC) populations are uniquely dependent on amino acid metabolism to drive the TCA cycle and oxidative phosphorylation. Oxidative phosphorylation can be selectively downregulated in de novo AML LSC populations by perturbing amino acid metabolism via BCL2 inhibition with venetoclax. While venetoclax-based therapies have shown high response rates, not all patients achieve remission. It may be possible to prospectively identify the patients who will most likely respond to venetoclax-based treatment by analyzing the metabolic properties of individual patients. Specifically, it appears that patients who are likely to be resistant to venetoclax-based therapy are able to employ alternate metabolic pathways to drive oxidative phosphorylation. Copyright © 2019. Published by Elsevier Ltd.

Report this publication

Statistics

Seen <100 times